BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15988143)

  • 1. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.
    Skvortsova I; Popper BA; Skvortsov S; Saurer M; Auer T; Moser R; Kamleitner H; Zwierzina H; Lukas P
    J Radiat Res; 2005 Jun; 46(2):241-8. PubMed ID: 15988143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
    Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
    J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
    Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influx of extracellular calcium participates in rituximab-enhanced ionizing radiation-induced apoptosis in Raji cells.
    Fengling M; Qingxiang G; Lijia Z; Wei Z
    Toxicol Lett; 2012 Mar; 209(3):221-6. PubMed ID: 22245670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
    Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
    Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation.
    Qiao Q; Jiang Y; Li G
    Oncol Rep; 2013 Jan; 29(1):380-6. PubMed ID: 23117293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
    Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin enhances (131)I-rituximab induced cell death in Raji cells.
    Kumar C; Pandey BN; Samuel G; Venkatesh M
    J Cancer Res Ther; 2015; 11(4):823-9. PubMed ID: 26881525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation.
    Fengling M; Fenju L; Wanxin W; Lijia Z; Jiandong T; Zu W; Xin Y; Qingxiang G
    Radiat Environ Biophys; 2009 Nov; 48(4):371-8. PubMed ID: 19652992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.
    Vega MI; Jazirehi AR; Huerta-Yepez S; Bonavida B
    J Immunol; 2005 Aug; 175(4):2174-83. PubMed ID: 16081784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-CD20 monoclonal antibody RTX enhances radiosensitivity of lymphoma cells].
    Min FL; Liu FJ; Wen WX; Zhai LJ; Zhou W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):660-5. PubMed ID: 20561423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S; Emmanouilides C; Bonavida B
    Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR; Bonavida B
    Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
    Kroger LA; DeNardo GL; Gumerlock PH; Xiong CY; Winthrop MD; Shi XB; Mack PC; Leshchinsky T; DeNardo SJ
    Cancer Biother Radiopharm; 2001 Jun; 16(3):213-25. PubMed ID: 11471486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.